This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459–68.
Zoi K, Cross NCP. Genomics of myeloproliferative neoplasms. J Clin Oncol. 2017;35:947–54.
Wang YL, Vandris K, Jones A, Cross NCP, Christos P, Adriano F, et al. JAK2 mutations are present in all cases of polycythemia vera. Leukemia. 2008;22:1289–1289.
Grisouard J, Li S, Kubovcakova L, Rao TN, Meyer SC, Lundberg P, et al. JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood. 2016;128:839–51.
Yao H, Ma Y, Hong Z, Zhao L, Monaghan SA, Hu M-C, et al. Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm. Leukemia. 2017;31:2122–31.
Godfrey AL, Chen E, Massie CE, Silber Y, Pagano F, Bellosillo B, et al. STAT1 activation in association with JAK2 exon 12 mutations. Haematologica. 2015;101:15–19.
Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011;117:2813–6.
Tefferi A, Lavu S, Mudireddy M, Lasho TL, Finke CM, Gangat N, et al. JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2 V617F mutated disease. Am J Hematol. 2018;93:E93–E96.
Cassinat B, Laguillier C, Gardin C, de Beco V, Burcheri S, Fenaux P, et al. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia. 2007;22:452–3.
Alvarez-Larran A, Ancochea A, Angona A, Pedro C, Garcia-Pallarols F, Martinez-Aviles L, et al. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica. 2012;97:1704–7.
Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007;21:1960–3.
Kouroupi E, Zoi K, Parquet N, Zoi C, Kiladjian J-J, Grigoraki V, et al. Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients: correspondence. Br J Haematol. 2008;142:676–9.
Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008;111:1686–9.
Yeh Y-M, Chen Y-L, Cheng H-Y, Su W-C, Chow N-H, Chen T-Y, et al. High percentage of JAK2 exon 12 mutation in asian patients with polycythemia vera. Am J Clin Pathol. 2010;134:266–70.
McKerrell T, Park N, Chi J, Collord G, Moreno T, Ponstingl H, et al. JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics. Blood Adv. 2017;1:968–71.
Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, et al. The evolutionary history of 2,658 cancers. Nature. 2020;578:122–8.
Blanche P, Dartigues J-F, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32:5381–97.
Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874–81.
Lakey MA, Pardanani A, Hoyer JD, Nguyen PL, Lasho TL, Tefferi A, et al. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations. Am J Clin Pathol. 2010;133:942–8.
Acknowledgements
This work was supported in part by grants from the French National Institute of Cancer (FIMBANK, INCa BCB 2013). The authors thank the Brest Biological Resources Center BB-0033–00037 (“CRB Santé du CHRU de Brest”) for providing high-quality annotated samples. The authors thank Laurence Sanhes, Célia Belkhodjia, Pascale Cony-Makhoul, Jérôme Poirot, Valérie Bardet, Gandhi Damaj and Loïc Garçon for providing clinical and biological data of patients.
Author information
Authors and Affiliations
Contributions
ST, DLP and VU conceived and designed the study. ST, FP, VU and DLP collected clinical data. JMC conceived and supervised the biological clinical database of FIMBANK. DLP, JR, ST, and VU analyzed and interpreted the data. DR, LLC, ST, DC, MM, BDR, LC, JCI, FB, CO, FG and JJK cared for the patients. DLP, ST and VU wrote the manuscript and OM, BC, JJK, JCI, EL and MH revised it critically.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Tondeur, S., Paul, F., Riou, J. et al. Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study. Leukemia 35, 871–875 (2021). https://doi.org/10.1038/s41375-020-0991-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-020-0991-x
This article is cited by
-
JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome
Journal of Cancer Research and Clinical Oncology (2023)
-
Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study
International Journal of Hematology (2022)
-
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
Leukemia (2021)
-
Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
Blood Cancer Journal (2021)